Please try another search
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; collaboration with Copenhagen University Hospital; collaboration with Intuitive Surgical, Inc. for robotics surgery in head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Andreas Kjaer | 60 | 2018 | CSO, CMO, Head of Scientific Advisory Board & Director |
Peter Morch Eriksen | 63 | 2019 | Independent Chairman |
Mats Thoren | 52 | 2021 | Vice Chairman of the Board |
Donna Haire | 55 | 2024 | Director |
Michael Thyring Engsig | 52 | 2023 | Independent Director |
Roger Gunnarsson | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review